RecruitingNCT03261089

Neuroprognostication Bias: A Collaboration to Reduce the Impact of Self-fulfilling Prophecy in Cardiac ARrEst

Addressing an Inherent Bias in Neuroprognostication: A Collaboration to Reduce the Impact of Self-fulfilling Prophecy in Cardiac ARrEst


Sponsor

Boston Medical Center

Enrollment

600 participants

Start Date

Aug 2, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

Cardiovascular disease remains the leading cause of death in the United States. Mortality rates of cardiac arrest range from 60-85%, and approximately 80% of survivors are initially comatose. Of those who survive, 50% are left with a permanent neurological disability, and only 10% are able to resume their former lifestyle. Early prognosis of comatose patients after cardiac arrest is critical for management of these patients, yet predicting outcome for these patients remains quite challenging. The primary study objective of SPARE is to assess the value of using a systematic, multi-modal approach for neuroprognostication in the unconscious post-cardiac arrest population. We hypothesize that prognostication using this approach will be significantly improved compared to historical controls. This approach will be novel because: All patients who are unconscious at least 24 hours post-cardiac arrest, whereas previous studies on neurologic outcome tended to have restrictive inclusion criteria, such as no pre-existing neurologic impairment (e.g. dementia or prior cerebrovascular injury), or included an unduly restrictive population, such as patients with a strictly comatose state. The prognostic modalities used to assess patients will be applied at specific time points that will maximize their utility. Patients' families and clinicians will be encouraged to provide adequate time to allow for a delayed recovery, especially in cases of uncertain outcome, thus minimizing the self-fulfilling prophesy bias of early withdrawal of life-sustaining therapies (WLST). This will be particularly pertinent in the comparison of US and Brazil/Italy patients, as the Brazilian and Italian populations are not commonly exposed to premature WLST (as can be the case in the US), one of the major sources of biases in prognostication studies of cardiac arrest due to the self-fulfilling prophecy.


Eligibility

Min Age: 18 YearsMax Age: 89 Years

Inclusion Criteria2

  • Initially unconscious following cardiac arrest from any non-perfusing rhythm (i.e., ventricular tachycardia, ventricular fibrillation, pulseless electrical activity, asystole)
  • Sustained return of spontaneous circulation (ROSC) as defined by maintained spontaneous circulation for at least 20 minutes after cardiopulmonary resuscitation.

Exclusion Criteria1

  • \- Isolated respiratory arrest without concomitant or ensuing cardiac arrest

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(8)

University of California, San Francisco

San Francisco, California, United States

Yale University

New Haven, Connecticut, United States

University of Florida

Gainesville, Florida, United States

Boston Medical Center

Boston, Massachusetts, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Instituto D'Or de Pesquisa e Ensino

Rio de Janeiro, Brazil

Albert Einstein Israelite Hospital

São Paulo, Brazil

Hospital das Clinicas Faculdade de Medicina Ribeirao Preto

São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03261089


Related Trials